Inflammation and Autoimmunity

Developing novel treatments for a breadth of inflammatory and autoimmune diseases

Seeking to develop best-in-class and first-in-class treatments for a breadth of inflammatory and autoimmune diseases with unmet medical needs

Leveraging our strength and expertise in immunology science, our research efforts are focused on gaining a better understanding of the common biology and shared molecular pathways among inflammatory and autoimmune diseases, as well as the fundamental drivers and mechanisms of disease. This approach enables us to identify and select drug targets that have the potential to effectively treat not just one, but multiple inflammatory and autoimmune diseases. Through our advancements in this field, we aim to bring value to the broader scientific community, help redefine standards of care and, ultimately, deliver breakthrough medicines that transform the lives of patients worldwide.

Focusing on unmet medical needs

  • Gout

    Gout is a chronic metabolic inflammatory disease caused by the build-up of uric acid crystals

    Watch video
  • Lupus

    Lupus attacks healthy tissue in the body, including skin, joints, the brain and blood vessels

  • Rheumatoid arthritis

    Rheumatoid arthritis is a painful, systemic, chronic inflammatory autoimmune disease which causes damage to the joints and vital organs

Day in the life – Micki Hultquist: committed to Lupus

Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Other (as at 2 February 2017)

Phase 1

Phase 1

  • MEDI0700 systemic lupus erythematosus
  • MEDI1814 Alzheimer’s disease
  • MEDI4920 primary Sjögren’s syndrome
  • MEDI7352 osteoarthritis pain
  • MEDI7734 myositis
  • anifrolumab systemic lupus erythematosus (subcutaneous)

Phase 2

Phase 2

  • AZD3241 multiple system atrophy
  • MEDI3902 prevention of nosocomial pseudomonas pneumonia
  • MEDI4893 hospital-acquired pneumonia/serious S. aureus infection
  • MEDI5872 primary Sjögren’s syndrome
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis
  • anifrolumab lupus nephritis
  • inebilizumab neuromyelitis optica
  • mavrilimumab rheumatoid arthritis
  • verinurad chronic treatment of hyperuricemia in patients with gout

Phase 3

Phase 3

  • AZD3293 AMARANTH DAYBREAK-ALZ Early Alzheimer's disease
  • anifrolumab TULIP systemic lupus erythematosus

LCM Projects

LCM Projects

  • Nexium stress ulcer prophylaxis
  • Nexium paediatrics
  • linaclotide irritable bowel syndrome with constipation (IBS-C)


Commitment to science

Our commitment to science is reflected in our track record of publications. Here are a few recent examples of high impact and high quality publications co-authored by AstraZeneca and/or MedImmune scientists.

Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy

May 2015

Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy

AstraZeneca/MedImmune AUTHOR
Tomas Mustelin (MedImmune)


Page Atlas ID: 1021237.011
Date of next review: November 2017